Table 2.

Indications for watchful waiting (with intention to treat)

Low or Intermediate risk prostate cancer

• Age < 75 years, life expectancy > 10 years

• Stage T1-T2a, Gleason score< 6

• PSA <8 ng/ml

• PSAD < 0.1(amount of PSA per gram of prostate tissue)

• Free/total PSA > 19%

• Patient choice

• One core + with < 30% involvement

Expectant management – Follow up

• Every 3-6 months

• DRE +PSA or PSA-DT, creatinine

• TRUS and biopsy if indicated

• Or biopsy every year

• Treatment – if tumour progression is present

• Patient choice

• PSA-DT<2 years or combination of above